Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Haas

Showing results (501-510 of 542) with videos related to

Pageof 55
Sort By:
Science (New York, N.Y.)|January 18, 2024
Impact of HLA class I functional divergence on HIV controlMathias Viard, Colm O'hUigin, Yuko Yuki, et al.
Pharmacogenetics and Genomics|November 24, 2011
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipientsKelly A Birdwell, Ben Grady, Leena Choi, et al.
The Journal of Infectious Diseases|September 22, 2017
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials ParticipantsKatie R Mollan, Camlin Tierney, Jacklyn N Hellwege, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Clinical Pharmacology and Therapeutics|September 30, 2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingR S Gammal, M H Court, C E Haidar, et al.
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
Tuberculosis (Edinburgh, Scotland)|December 6, 2018
Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meetingYuri F van der Heijden, Fareed Abdullah, Bruno B Andrade, et al.
Human Molecular Genetics|June 22, 2012
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African AmericansPaul J McLaren, Stephan Ripke, Kimberly Pelak, et al.
Pharmacogenetics and Genomics|October 19, 2006
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger, Marylyn D Ritchie, Robert W Shafer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2020
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing RegimensMichael A Leonard, Zinhle Cindi, Yuki Bradford, et al.
Pageof 55

Showing results (501-510 of 542) with videos related to

Sort By:
Pageof 55
Science (New York, N.Y.)|January 18, 2024
Impact of HLA class I functional divergence on HIV controlMathias Viard, Colm O'hUigin, Yuko Yuki, et al.
Pharmacogenetics and Genomics|November 24, 2011
The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipientsKelly A Birdwell, Ben Grady, Leena Choi, et al.
The Journal of Infectious Diseases|September 22, 2017
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials ParticipantsKatie R Mollan, Camlin Tierney, Jacklyn N Hellwege, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasmaD W Haas, L A Clough, B W Johnson, et al.
Clinical Pharmacology and Therapeutics|September 30, 2015
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir PrescribingR S Gammal, M H Court, C E Haidar, et al.
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
Tuberculosis (Edinburgh, Scotland)|December 6, 2018
Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meetingYuri F van der Heijden, Fareed Abdullah, Bruno B Andrade, et al.
Human Molecular Genetics|June 22, 2012
Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African AmericansPaul J McLaren, Stephan Ripke, Kimberly Pelak, et al.
Pharmacogenetics and Genomics|October 19, 2006
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger, Marylyn D Ritchie, Robert W Shafer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 24, 2020
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing RegimensMichael A Leonard, Zinhle Cindi, Yuki Bradford, et al.
Pageof 55